Journal
ALZHEIMERS RESEARCH & THERAPY
Volume 15, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13195-023-01321-7
Keywords
Alzheimer's disease; Drug development; Frontotemporal dementia; Progressive supranuclear palsy; Corticobasal degeneration; Chronic traumatic encephalopathy; Tau; Tauopathy; Therapeutic pipeline; Pick's disease; Argyrophilic grain disease; Primary age-related tauopathy
Categories
Ask authors/readers for more resources
Tauopathies are neurodegenerative disorders characterized by the aggregation of tau protein. There are currently no effective treatments, but several drug candidates are in clinical trials and there is evidence that therapeutic approaches may slow disease progression or improve symptoms.
Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed to be implicated in neuronal death, which leads to a range of symptoms including cognitive decline, behavioral change, dementia, and motor deficits. Currently, there are no effective treatments for tauopathies. There are four clinical candidates in phase III trials and 16 in phase II trials. While no effective treatments are currently approved, there is increasing evidence to suggest that various therapeutic approaches may slow the progression of tauopathies or improve symptoms. This review outlines the landscape of therapeutic drugs (indexed through February 28, 2023) that target tau pathology and describes drug candidates in clinical development as well as those in the discovery and preclinical phases. The review also contains information on notable therapeutic programs that are inactive or that have been discontinued from development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available